{"title":"中性粒细胞-淋巴细胞比率的变化可预测膀胱癌手术后的早期复发","authors":"Rumeysa Çolak, Gökmen Umut Erdem, Caner Kapar, İlkay Gültürk, Faruk Aksu, Gülçin Şahingöz Erdal, Mesut Yılmaz, Deniz Tural","doi":"10.1111/ajco.14065","DOIUrl":null,"url":null,"abstract":"BackgroundRecurrence develops in 50% of operated bladder cancer patients. It is important to detect recurrence in advance, and there is no prognostic reliable biomarker for bladder cancer.ObjectiveThe aim of this study is to show that changes in hematological parameters before radiological imaging can predict recurrence.MethodsWe performed a retrospective cohort study of patients undergoing radical cystectomy for urothelial carcinoma of the bladder identified using our institutional database (2010–2022). Disease‐free survival (DFS) was evaluated as relapse or death due to any cause. Kaplan‐Meier analysis was used for DFS according to the follow‐up period. DFS was calculated in two groups neutrophil‐lymphocyte ratio (NLR) < 3 and NLR ≥ 3. Log‐rank test was used for comparison between groups and <jats:italic>p</jats:italic> < 0.05 was considered statistically significant.ResultsIn the study, 91 patients were examined. The median age was 61.0 (34–79). 57.1% of the patients were T (1–2) and 42.9% were T (3–4). The lymph node (LN) was negative in 78% and positive in 22%. Median follow‐up time and DFS were 53.4 months and 54%, respectively. The median NLR was 2.8 (0.8–8.7). For DFS, there was a significant difference according to age, T stage, and LN status (p: 0.048, 0.019, and 0.040). There was no significant difference in the NLR in terms of DFS at the time of diagnosis (p: 0.654). In follow‐ups; While there was no difference in the NLR for DFS 12 months before recurrence (p: 0.231), there was a significant difference 6 months before the relapse and at the time of recurrence (p: 0.023 and 0.031).ConclusionThe change in the NLR before radiological recurrence in bladder cancer is significant in predicting recurrence. Prospective and multi‐center research is needed to confirm our findings.","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Change in the neutrophil‐lymphocyte ratio may predict early recurrence in operated bladder cancer\",\"authors\":\"Rumeysa Çolak, Gökmen Umut Erdem, Caner Kapar, İlkay Gültürk, Faruk Aksu, Gülçin Şahingöz Erdal, Mesut Yılmaz, Deniz Tural\",\"doi\":\"10.1111/ajco.14065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BackgroundRecurrence develops in 50% of operated bladder cancer patients. It is important to detect recurrence in advance, and there is no prognostic reliable biomarker for bladder cancer.ObjectiveThe aim of this study is to show that changes in hematological parameters before radiological imaging can predict recurrence.MethodsWe performed a retrospective cohort study of patients undergoing radical cystectomy for urothelial carcinoma of the bladder identified using our institutional database (2010–2022). Disease‐free survival (DFS) was evaluated as relapse or death due to any cause. Kaplan‐Meier analysis was used for DFS according to the follow‐up period. DFS was calculated in two groups neutrophil‐lymphocyte ratio (NLR) < 3 and NLR ≥ 3. Log‐rank test was used for comparison between groups and <jats:italic>p</jats:italic> < 0.05 was considered statistically significant.ResultsIn the study, 91 patients were examined. The median age was 61.0 (34–79). 57.1% of the patients were T (1–2) and 42.9% were T (3–4). The lymph node (LN) was negative in 78% and positive in 22%. Median follow‐up time and DFS were 53.4 months and 54%, respectively. The median NLR was 2.8 (0.8–8.7). For DFS, there was a significant difference according to age, T stage, and LN status (p: 0.048, 0.019, and 0.040). There was no significant difference in the NLR in terms of DFS at the time of diagnosis (p: 0.654). In follow‐ups; While there was no difference in the NLR for DFS 12 months before recurrence (p: 0.231), there was a significant difference 6 months before the relapse and at the time of recurrence (p: 0.023 and 0.031).ConclusionThe change in the NLR before radiological recurrence in bladder cancer is significant in predicting recurrence. Prospective and multi‐center research is needed to confirm our findings.\",\"PeriodicalId\":8633,\"journal\":{\"name\":\"Asia-Pacific journal of clinical oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asia-Pacific journal of clinical oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ajco.14065\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.14065","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Change in the neutrophil‐lymphocyte ratio may predict early recurrence in operated bladder cancer
BackgroundRecurrence develops in 50% of operated bladder cancer patients. It is important to detect recurrence in advance, and there is no prognostic reliable biomarker for bladder cancer.ObjectiveThe aim of this study is to show that changes in hematological parameters before radiological imaging can predict recurrence.MethodsWe performed a retrospective cohort study of patients undergoing radical cystectomy for urothelial carcinoma of the bladder identified using our institutional database (2010–2022). Disease‐free survival (DFS) was evaluated as relapse or death due to any cause. Kaplan‐Meier analysis was used for DFS according to the follow‐up period. DFS was calculated in two groups neutrophil‐lymphocyte ratio (NLR) < 3 and NLR ≥ 3. Log‐rank test was used for comparison between groups and p < 0.05 was considered statistically significant.ResultsIn the study, 91 patients were examined. The median age was 61.0 (34–79). 57.1% of the patients were T (1–2) and 42.9% were T (3–4). The lymph node (LN) was negative in 78% and positive in 22%. Median follow‐up time and DFS were 53.4 months and 54%, respectively. The median NLR was 2.8 (0.8–8.7). For DFS, there was a significant difference according to age, T stage, and LN status (p: 0.048, 0.019, and 0.040). There was no significant difference in the NLR in terms of DFS at the time of diagnosis (p: 0.654). In follow‐ups; While there was no difference in the NLR for DFS 12 months before recurrence (p: 0.231), there was a significant difference 6 months before the relapse and at the time of recurrence (p: 0.023 and 0.031).ConclusionThe change in the NLR before radiological recurrence in bladder cancer is significant in predicting recurrence. Prospective and multi‐center research is needed to confirm our findings.
期刊介绍:
Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.